CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

OTCQB:CYDY - Post by User

CytoDyn Inc > When this moves to Nasdaq buckle up

<< Previous

Bullboard Posts

Next >>

Comment by theNormon Feb 01, 2021 3:42pm

88 Views

Post# 32439253

RE:When this moves to Nasdaq buckle up

I was holding IPA and this. Today I added positions in XSPA (NASDAQ) and MEDV which also trades otcqb COPRF Arbitrage op right now with otc listing up 9% vs NEO cdn listing down 3.57% with Feb 4 UCLA webinar just announced.

XSPA is burning through warrant buying for Dec H.C. Wainwright prospectus, the same high calibre IR who work with IPA now. When warrants finish, it will lift off with spa's and new testing kiosks in airports across the globe. Cheers

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China